Quantcast
Last updated on April 21, 2014 at 7:52 EDT

MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference

March 14, 2013

KENNESAW, Ga., March 14, 2013 /PRNewswire/ — MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago. Parker H. “Pete” Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on March 19(th) at 3:20 p.m. CDT/4:20 p.m. EDT at the Westin Michigan Avenue. A webcast of this presentation will be available on the Company’s website, www.mimedx.com.

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix(TM), and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 130,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx, Inc.


Source: PR Newswire